雄黄在多发性骨髓瘤治疗中的作用  

Realgar in the treatment for multiple myeloma

作　　者：王梦昌[1] 刘陕西[1] 李信民[1] 

机构地区：[1]西安交通大学第一医院血液科,西安710061

出　　处：《临床血液学杂志》2003年第6期249-251,共3页Journal of Clinical Hematology

摘　　要：目的 :研究雄黄治疗多发性骨髓瘤 (MM )的作用机制 ,并对其临床效果进行观察。方法 :采用MTT法、双抗体夹心ELISA法检测 15例MM患者应用雄黄治疗前后血清中白细胞介素 6 (IL 6 )活性及其受体 (sIL 6R)水平。结果 :MM患者血清中IL 6活性及sIL 6R水平明显高于健康对照组 (P <0 .0 1) ;应用雄黄治疗 5 0天后 ,MM患者血清中IL 6活性及sIL 6R水平无明显降低 (P >0 .0 5 ) ,Ⅲ期MM患者的IL 6活性显著高于Ⅰ、Ⅱ期 (P <0 .0 5 ) ,但sIL 6R水平两者差异无显著性意义 (P >0 .0 5 )。用雄黄治疗 15例患者 ,3例完全缓解 ,5例有效 ,7例无效。结论 :雄黄可能不是通过降低IL 6活性及sIL 6R水平来抑制肿瘤细胞生长的。Objective:To observe the clinical effect of realgar on multiple myeloma and to investigate the mechanism of its role.Method:MTT and Biantibody cramped ELISA assay were used to detect the activity of interleukin-6(IL-6) and level of soluble interleukin-6 receptor(sIL-6R) of the serum in 15 multiple myeloma patients with or without Realgar.Result:The activity of interleukin-6 and level of soluble interleukin-6 receptor of multiple myeloma patients were significantly higher than that of control group(P< 0.01). They did not decrease apparently after realgar was used for 50 days(P> 0.05).The interleukin-6 activity of stage Ⅲ patients were much higher than that of stage Ⅰ or Ⅱ patients(P< 0.05). There was no difference of the level of soluble interleukin-6 Receptor between two groups(P> 0.05). For 15 patients who used Realgar,3 attained CR, 5 attained PR.Conclusion:Realgar could not decrease the activity of interleukin-6 and the level of soluble interleukin-6 receptor so as to inhibit the proliferation of tumor cells.

关 键 词：骨髓瘤 多发性 雄黄 IL-6 治疗 

分 类 号：R733.31[医药卫生—肿瘤]